IJO International Journal of Oncology 1019-6439 1791-2423 D.A. Spandidos 10.3892/ijo.2012.1595 ijo-41-05-1619 Articles Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families NOVAKOVIĆSRDJAN1 MILATOVIĆMAŠA1 CERKOVNIKPETRA1 STEGELVIDA1 KRAJCMATEJA2 HOČEVARMARKO3 ŽGAJNARJANEZ3 VAKSELJALEŠ4 Department of Molecular Diagnostics Unit of Genetic Counseling Department of Surgical Oncology Unit of Gynecological Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia Correspondence to: Professor Srdjan Novaković, Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Zaloska 2, Ljubljana 1000, Slovenia, E-mail: snovakovic@onko-i.si 11 2012 21 08 2012 41 5 1619 1627 06 06 2012 27 07 2012 Copyright © 2012, Spandidos Publications 2012

This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

The estimated proportion of hereditary breast and ovarian cancers among all breast and ovarian cancer cases is 5–10%. According to the literature, inherited mutations in the BRCA1 and BRCA2 tumour-suppressor genes, account for the majority of hereditary breast and ovarian cancer cases. The aim of this report is to present novel mutations that have not yet been described in the literature and pathogenic BRCA1 and BRCA2 mutations which have been detected in HBOC families for the first time in the last three years. In the period between January 2009 and December 2011, 559 individuals from 379 families affected with breast and/or ovarian cancer were screened for mutations in the BRCA1 and BRCA2 genes. Three novel mutations were detected: one in BRCA1 - c.1193C>A (p.Ser398*) and two in BRCA2 - c.5101C>T (p.Gln1701*) and c.5433_5436delGGAA (p.Glu1811Aspfs*3). These novel mutations are located in the exons 11 of BRCA1 or BRCA2 and encode truncated proteins. Two of them are nonsense while one is a frameshift mutation. Also, 11 previously known pathogenic mutations were detected for the first time in the HBOC families studied here (three in BRCA1 and eight in BRCA2). All, except one cause premature formation of stop codons leading to truncation of the respective BRCA1 or BRCA2 proteins.

 hereditary breast/ovarian cancer mutation screening BRCA1 BRCA2 Introduction

Most breast and ovarian cancers are sporadic and only about 5–10% of breast and 10% of ovarian cancers are thought to be hereditary, causing the hereditary breast and ovarian cancer (HBOC) syndrome (1,2). Majority of HBOC cases have underlying cause in germline mutations in the BRCA1 and BRCA2 susceptibility genes (3,4). Carriers of known deleterious mutations in the BRCA genes have a lifetime risk of approximately 60 to 80% for development of breast cancer (BC) and a 15 to 40% lifetime risk for ovarian cancer (OC) and are also at a heightened risk for some other cancer types (4–6). So far, genome-wide association studies have not identified other highly penetrant susceptibility genes linked with HBOC, as reviewed in Mavaddat et al(7). Genetic screening of BRCA1 and BRCA2 therefore remains the only verified strategy for identification of individuals at high risk for hereditary BC and/or OC. To reduce cancer risk, healthy carriers of deleterious BRCA mutations are presented with various preventive options, such as regular intensive screenings, prophylactic mastectomy with breast reconstruction and/or oophorectomy or chemoprevention in the setting of a clinical trial (8,9). Additionally, genetic counseling and BRCA screening can be offered to first degree relatives of the carrier.

The present report continues the previous report of our group from 2011 where pathogenic mutations in the BRCA1 and BRCA2 genes in the Slovene population were described (10). We describe novel pathogenic mutations that have not yet been described in the literature or BRCA mutational databases, such as Breast Cancer Information Core Database (BIC), Human Gene Mutation Database (HGMD-Professional), Universal Mutation Database (UMD) and Leiden Open Variation Database (LOVD). We also report pathogenic mutations for which records already exist but were detected for the first time in the Slovene HBOC families tested between January 2009 and December 2011. The possible effects of novel and pathogenic BRCA1 and BRCA2 mutations which have been detected in Slovene HBOC families for the first time are discussed.

 Patients and methods <sec> <title>Tested individuals

In the period from January 2009 to December 2011, 559 new individuals from 379 Slovene HBOC families were submitted through mutational screening of the BRCA1 and/or the BRCA2 genes at the Institute of Oncology Ljubljana, which is the only public institution performing BRCA screenings in Slovenia. Probands were chosen after genetic counseling according to the ASCO guidelines for genetic and genomic testing for cancer susceptibility (11). The family history data were verified in the Slovenian state cancer registry established in 1950. All tested individuals provided written informed consent and attended genetic counseling sessions before and after testing.

 Mutation screening

In 362 probands admitted for complete screening of all BRCA1/2 exons, methods for variations searching consisted of multiplex ligation-dependent probe amplification analysis (MLPA; MRC Holland, Amsterdam, Netherlands) for detection of large genomic deletions and insertions and screening for small mutations of all BRCA1 and BRCA2 exons with high-resolution melting (HRM), denaturing gradient gel electrophoresis (DGGE) and direct sequencing methods (10). Probands (197) from cancer-affected families with already confirmed pathogenic BRCA mutation were tested only for the familial pathogenic mutation. The nomenclature of this study follows the Nomenclature for Description of Genetic Variations approved by the Human Genome Variation Society (HGVS).

 Results

Since the screening for BRCA mutations began in Slovenia in the year 1999, altogether 45 distinct pathogenic BRCA mutations have been detected in the tested Slovene families - 22 in the BRCA1 and 23 in the BRCA2 (Table I). The overall mutation detection rates for the period between January 1999 to December 2008 and from January 2009 to December 2011 were 29.8 and 21.2%, respectively (Table II). The majority of detected pathogenic mutations were nonsense mutations creating premature stop codons or missense mutations and small deletions and/or insertions that cause frameshifting and also lead to premature termination of translation. Of all detected BRCA1 mutations four were large deletions, all of more than one exon. No large deletions or insertions were detected in the BRCA2 gene so far. In the period of the last three years (January 2009 to December 2011) 559 probands were tested either for the known familial mutation or were submitted through the complete screening of all BRCA exons (Table II). Of the tested probands 115 were positive for BRCA1 pathogenic mutation and 41 for BRCA2 pathogenic mutation. In the stated period, three novel mutations were found which have not yet been described, one in the BRCA1 and two in the BRCA2 gene (Table III). The novel BRCA1 pathogenic mutation was detected in a healthy female from a HBOC family (Table III, Fig. 1). All novel BRCA2 mutations were detected in female BC patients (Table III, Fig. 1).

Besides three novel mutations, eleven known pathogenic BRCA mutations were discovered for the first time in the Slovene HBOC families, three BRCA1 and eight BRCA2 (Tables IV and V). All these newly detected pathogenic mutations were detected in female BC and/or OC patients (Tables IV and V). All novel and newly detected pathogenic mutations in Slovenia were small mutations dictating premature stop codon formation and subsequent truncation of BRCA1 or BRCA2 proteins.

 Discussion

Several recent studies have associated specific BRCA mutations with specific cancer risks and phenotypes (12,13). Many HBOC studies therefore have focused on predicting effects of specific BRCA mutations and reveal possible underlying molecular mechanisms (7). In this context, we discuss here the predicted effects of the individual novel and newly detected Slovene BRCA1 and BRCA2 pathogenic mutations.

<sec> <title>Novel mutations

All three novel mutations described here -c.1193C>A (p.Ser398*) in the BRCA1 and c.5101C>T (p.Gln1701*) and c.5433_5436delGGAA (p.Glu1811Aspfs*3) in the BRCA2 gene are located in exon 11 of BRCA1 or BRCA2, which is the largest exon in both genes and also carry the majority of pathogenic mutations described so far. As BRCA mutations causing truncation of the BRCA proteins are regarded as pathogenic, with some exceptions of truncating mutations in the last 27th exon of the BRCA2, we predict that all three novel mutations have deleterious effects (14,15). More detailed descriptions are given below.

 BRCA1

Mutation c.1193C>A (p.Ser398*) in exon 11 causes stop codon formation at codon 398. In the BIC database a similar mutation discovered in Asian population, which leads to formation of stop codon 398 (c.1193C>G), is described as a clinically significant variant, but no references are given. Codon 398 lies in one of five conserved regions located at the 5′ end of exon 11 (codons 282–554), which include putative interacting sites for several proteins thought to be involved in transcription (16). Codon 398 also forms a part of interacting site (codons 341–748) for DNA repair protein RAD50 which participates in DNA repair by homologous recombination and by non-homologous end joining (16,17). Accordingly, we predict c.1193C>A mutation to severely impair BRCA1-mediated DNA repair.

 BRCA2

Mutation c.5101C>T (p.Gln1701*) is a nonsense mutation causing formation of a stop codon at position 1701 which is located in exon 11 in the ovarian cancer cluster region (OCCR) spanning nucleotides 3035 to 6629. Several studies have shown that truncating mutations in the OCCR region confer a higher ratio of ovarian cancer relative to breast cancer (18–20). Also, higher risk of prostate cancer was recently detected in males with mutations in the BRCA2 OCCR region (21). Consistently with these studies, one of the two Slovene BRCA2 c.5101C>T families exhibits a high incidence of OC, besides BC (Table III).

Frameshift mutation c.5433_5436delGGAA (p.Glu1811 Aspfs*3) results in translation termination at amino acid position 1813, which lies within the BRC repeat region in exon 11, between BRC5 (amino acids 1649–1735) and BRC6 (amino acids 1822–1914). Jara et al described a similar mutation, c.5439delT (p.Leu1813fs*1), that might be disease-causing (22). This mutation dictates formation of a stop codon at amino acid position 1814 in the BRC repeat region (22).

The BRC repeat region is a region of eight highly conserved internal BRC repeats separated by conserved nucleotide stretches (23,24). The eight BRC repeats bind the RAD51 recombinase and control its activity in homologous DNA recombination (23,24). Truncating mutation within the BRCA2 BRC repeat domain, such as the novel c.5433_5436delGGAA, are therefore predicted to seriously impair the cell’s ability to repair DNA double-strand breaks (23–25).

 Known BRCA pathogenic mutations that have been detected for the first time in Slovene HBOC families BRCA1

From January 2009 to December 2011 three known pathogenic mutations in the BRCA1 and eight in the BRCA2 gene were detected for the first time in the Slovene HBOC families. Except one, all cause premature formation of stop codons leading to truncation of the respective BRCA1 or BRCA2 proteins.

The mutation c.66_67delAG (p.Glu23Valfs*17) is the most common BRCA1 mutation worldwide which occurs at a frequency of 1.1% in the Ashkenazi Jews (26). Despite being so widespread, this is the first recording of c.66_67delAG in Slovenia, which to note has only very small Jewish population (estimated 500–1,000 people). The c.66_67delAG dictates formation of stop codon in the BRCA1 exon 2 thus forming a truncated BRCA1 protein, BRAt, which lacks all known BRCA1 functional domains (26). Studies have shown that besides being non-functional the truncated BRCA proteins can also impair the function of wild-type BRCA proteins (26,27). It was further suggested that the BRAt mutant protein increases transcription of the protein maspin (mammary serine protease inhibitor), which has been implicated in inhibition of growth, invasion, and metastatic potential of cancer cells (26,28). Jiang et al also demonstrated that maspin sensitizes BRCA deficient breast carcinoma cells to staurosporine-induced apoptosis thus leading to an increased chemosensitivity (29).

The other two newly detected BRCA1 mutations are located in exon 11. Mutation c.3718C>T (p.Gln1240*) is reported few times in the BRCA mutational databases but is published only once by Kwong et al, who detected it in an endometrial cancer patient of European origin (30). We detected the c.3718C>T in two Slovene families who are, interestingly, both affected by various cancer types (Table IV). As this mutation was first detected in endometrial cancer, this could imply that the c.3718C>T predisposes to other cancer types besides BC/OC. Further studies are needed to corroborate this observation and uncover possible underlying molecular mechanisms.

Mutation c.3436_3439delTGTT (p.Cys1146Leufs*8) in the 11th exon of BRCA1 was before only found once in the Slovene neighboring country Austria (31). It is predicted to cause termination of protein translation at codon 1153. It can be compared to a similar mutation c.3481_3491del11 (p.Glu1161Phefs*3) that creates stop codon at 1163 (32). The c.3481_3491del11 is a widespread French founder mutation that is frequently detected in hereditary OC (33,34). Comparably, the Slovene c.3436_3439delTGTT family is characterized by higher incidence of OC relative to BC. Future studies are needed to determine whether increased incidence of OC is associated with specific exon 11 truncating BRCA1 mutations.

 BRCA2

The eight newly detected BRCA2 mutations are all rather rare with only few existing records or publications. Mutation c.262_263delCT (p.Leu88Alafs*12) is located in exon 3. It was first described in one Polish HBOC family (described as 488_489delCT) and was recently detected in a Spanish BC patient (35,36). Salgado et al suggested that abrogation of the amino-terminal exon 3 transcription activation domain in the BRCA2 protein affects BRCA2 role in transcriptional regulation and DNA repair processes through replication protein A (RPA) (36). They further suggested that abrogation of most (3320 amino acids) of the 3418 BRCA2 amino acids has more severe biological consequences besides disrupted transcriptional regulation (36).

Mutation, c.658_659delGT (p.Val220Ilefs*4), is located in exon 8 and is predicted to truncate the protein before the eight BRC repeats (37). Interestingly, the c.658_659delGT is one of a few BRCA2 mutations found in BRCA2 biallelic cases. These biallelic BRCA2 mutations are known to cause the D1 subgroup of Fanconi anemia (FA-D1), a rare autosomal recessive disorder characterized, among other defects, by predisposition to several childhood cancers (38,39). Studies have shown that FA-D1 patients are especially at a high risk of developing brain tumors, in particular medulloblastomas, compared to other subgroups which are caused by mutations in other DNA-repair genes (40). To note, BC and OC risk in biallelic BRCA2 patients is difficult to determine as FA patients usually die at a young age, before BC or OC would generally develop. Nevertheless, it could be useful to follow whether carriers of monoallelic c.658_659delGT are also burdened by an increased risk for medulloblastomas or other brain tumors. The Slovene family which has monoallelic BRCA2 c.658_659delGT does not, however, exhibit any brain tumors and is affected mostly by quite late onset of OC. No biallelic BRCA2 mutations were detected in Slovenia so far.

Mutation c.1773_1776delTTAT (p.Ile591Metfs*22) causes formation of a stop codon 612 in the exon 10 of BRCA2. It has been described for Western European and Chinese population (41–43). A similar truncating deletion c.1787_1799del13 forming stop codon near at 609 was recently discovered in a prostate cancer patient with family history of stomach cancer but no BC or OC (44). No functional characterizations have yet been published for c.1773_1776delTTAT, however, the Slovene family having c.1773_1776delTTAT is to date affected only by BC (Table V).

Three BRCA2 mutations were detected in the exon 11, c.5213_5216delCTTA, c.6641insC and c.6814delA. Mutation c.5213_5216delCTTA (p.Thr1738Ilefs*2) in exon 11 has been already found in several HBOC families, mainly in the USA, the Netherlands and in Belgium (45–49). It causes formation of termination signal at codon 1739 located between BRC5 and BRC6 in the BRC repeat region, similarly to the novel mutation c.5433_5436delGGAA discussed above. According to the literature no other cancers besides BC and OC are associated with this mutation. This also applies to the Slovene c.5213_5216delCTTA family.

Mutation c.6641insC (p.Thr2214Asnfs*10) in exon 11 is a frameshift mutation reported only once in BIC database. Mutation is predicted to form a stop codon at position 2223 located at the 3′ end of exon 11. The mutation is causing the truncated BRCA2 protein for the subsequent exons 12 to 27. Mutation c.6641insC was identified in Slovene BC patient diagnosed at age 47, with a history of two BC cases in her family, diagnosed at ages 36 and 44. Interestingly, one was male BC (Table V). Similar mutation c.6641dupC (p.Lys2215Tyrfs*10) was detected in nearby Croatia in two unrelated families (50).

Mutation c.6814delA (p.Arg2272Glufs*8) in exon 11 was detected in Slovene BC patient diagnosed at 32 years of age, whose mother had bilateral BC. It is described only once in the UMD database, without references, and is predicted to form stop codon at position 2279 near the 3′ end of exon 11, therefore abrogating exons 12 to 27.

Mutation c.8175G>A (p.Trp2725*) was first reported just recently by Levanat et al(50). Mutation c.8175G>A was identified in two unaffected siblings (with a family history of two BC cases) from Croatia (50). Mutation c.8175G>A lies in the frequently mutated exon 18 of BRCA2 leading to the truncation of the BRCA2 oligonucleotide binding domain (OB1) in the DNA-binding domain (DBD) (32). The BRCA2 DBD region is needed for binding of single-stranded DNA (ssDNA) that results from DNA damage or replication errors (51). Through this binding of ssDNA the BRCA2 protein mediates delivery of RAD51 to the sites of exposed single-stranded DNA thus enabling the RAD51 to catalyze homologous pairing and DNA strand exchange (51). Through affecting this recruitment of RAD51 to the ssDNA, mutations in the BRCA2 DBD are predicted to affect the homologous recombination needed for maintaining the integrity of the genome. Besides binding ssDNA, OB1 also binds the 70-amino acid DSS1 which is needed for BRCA2 stability and is also crucial for the BRCA2 functioning in one of the homologous recombination pathways (52,53).

Mutation c.9117G>A (p.Pro3039Pro) is located in exon 23 of BRCA2. This splicing mutation was shown to be truncating (54). By this mutation the OB2 functional domain of BRCA2 protein is affected most probably causing impaired repair of double-strand DNA breaks (51,55). Mutation c.9117G>A was identified in three tested members from one Slovene family. Proband (mother) was diagnosed with BC at the age of 49. Her two daughters were both identified as carriers; one diagnosed with OC at the age 24 and one still unaffected. Mutation c.9117G>A has been already found in several HBOC families of Western/Central/East European origin (56).

The present report describes three novel BRCA pathogenic mutations that have been detected in Slovene HBOC families thereby contributing to the ever-expanding spectrum of the world-wide pathogenic BRCA mutations. Eleven previously known pathogenic mutations that have been discovered for the first time in Slovenia are also presented. For the probands bearing novel or pathogenic BRCA1 and BRCA2 mutations which have been detected in Slovene population for the first time, relevant clinical data and family history are given. Recent literature is reviewed to provide new data, which should help to create specific plans for preventive and/or therapeutic strategies for individual carriers according to their specific mutation.

The authors gratefully thank the genetic counselors and nurses as well as laboratory technicians who helped to recruit patients, collect their clinical data and performed the analyses - Nikola Bešič, Alenka Vrečar and Simona Traven.

 References FerlayJParkinDMSteliarova-FoucherEEstimates of cancer incidence and mortality in Europe in 2008Eur J Cancer467657812010 JamesCRQuinnJEMullanPBJohnstonPGHarkinDPBRCA1, a potential predictive biomarker in the treatment of breast cancerOncologist121421502007 XuJWangBZhangYLiRWangYZhangSClinical implications for BRCA gene mutation in breast cancerMol Biol Rep39309731022012 LynchHTSilvaESnyderCLynchJFHereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromesBreast J143132008 ThompsonDEastonDFBreast Cancer Linkage ConsortiumCancer incidence in BRCA1 mutation carriersJ Natl Cancer Inst94135813652002 KadouriLBercovichDElimelechAA novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancerBMC Cancer7142007 MavaddatNAntoniouACEastonDFGarcia-ClosasMGenetic susceptibility to breast cancerMol Oncol41741912010 KoumpisCDimitrakakisCAntsaklisAPrevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from GreeceHered Cancer Clin Pract9102011 MetcalfeKASempleJLNarodSATime to reconsider subcutaneous mastectomy for breast-cancer prevention?Lancet Oncol64314342005 StegelVKrajcMZgajnarJThe occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian populationBMC Med Genet1292011 RobsonMEStormCDWeitzelJWollinsDSOffitKAmerican Society of Clinical OncologyAmerican Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibilityJ Clin Oncol288939012010 RoyRChunJPowellSNBRCA1 and BRCA2: different roles in a common pathway of genome protectionNat Rev Cancer1268782012 TungNWangYCollinsLCEstrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic featuresBreast Cancer Res12R122010 RadicePDe SummaSCalecaLTommasiSUnclassified variants in BRCA genes: guidelines for interpretationAnn Oncol22Suppl 1i18i232011 BorgAHaileRWMaloneKECharacterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE studyHum Mutat31E1200E12402010 FlemingMAPotterJDRamirezCJOstranderGKOstranderEAUnderstanding missense mutations in the BRCA1 gene: an evolutionary approachProc Natl Acad Sci USA100115111562003 ZhongQBoyerTGChenPLLeeWHDeficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblastsCancer Res62396639702002 GaytherSAMangionJRussellPVariation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 geneNat Genet151031051997 ThompsonDEastonDVariation in cancer risks, by mutation position, in BRCA2 mutation carriersAm J Hum Genet684104192001 HamannULiuXLangeSUlmerHUBennerAScottRJContribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in GermanyJ Med Genet39E122002 MoranAO’HaraCKhanSRisk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutationsFam Cancer112352422012 JaraLAmpueroSSantibanezEBRCA1 and BRCA2 mutations in a South American populationCancer Genet Cytogenet16636452006 RajendraEVenkitaramanARTwo modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinaseNucleic Acids Res3882962010 ShivjiMKMukundSRRajendraEThe BRC repeats of human BRCA2 differentially regulate RAD51 binding on single-versus double-stranded DNA to stimulate strand exchangeProc Natl Acad Sci USA10613254132592009 JensenRBCarreiraAKowalczykowskiSCPurified human BRCA2 stimulates RAD51-mediated recombinationNature4676786832010 O’DonnellJDLingerRJKrukPABRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cellsGynecol Oncol1162622682010 KingTALiWBrogiEHeterogenic loss of the wild-type BRCA allele in human breast tumorigenesisAnn Surg Oncol14251025182007 StreuliCHMaspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivoBreast Cancer Res41371402002 JiangNMengYZhangSMensah-OsmanEShengSMaspin sensitizes breast carcinoma cells to induced apoptosisOncogene21408940982002 KwongANgEKTangEYA novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancerFam Cancer102332372011 WagnerTStoppa-LyonnetDFleischmannEDenaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutationsGenomics623693761999 CaputoSBenboudjemaLSinilnikovaORouleauEBeroudCLidereauRDescription and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databasesNucleic Acids Res40D992D10022012 JanezicSAZiogasAKrumroyLMGermline BRCA1 alterations in a population-based series of ovarian cancer casesHum Mol Genet88898971999 MusolinoAMichiaraMBellaMAMolecular profile and clinical variables in BRCA1-positive breast cancers. A population-based studyTumori915055122005 GorskiBJakubowskaAHuzarskiTA high proportion of founder BRCA1 mutations in Polish breast cancer familiesInt J Cancer1106836862004 SalgadoJGutierrezCGilCRoblesMGarcia-FoncillasJComparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2Breast Cancer Res Treat1232912932010 FrankTSManleySAOlopadeOISequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer riskJ Clin Oncol16241724251998 AdankMASegersHvan MilSEFanconi anemia gene mutations are not involved in sporadic Wilms tumorPediatr Blood Cancer557427442010 HowlettNGTaniguchiTOlsonSBiallelic inactivation of BRCA2 in Fanconi anemiaScience2976066092002 AlterBPRosenbergPSBrodyLCClinical and molecular features associated with biallelic mutations in FANCD1/BRCA2J Med Genet44192007 MaZLCaoMZLiWFAnalysis of BRCA2 gene mutations among familial and/or early-onset breast cancer patients in eastern Shandong of ChinaZhonghua Yi Xue Yi Chuan Xue Za Zhi251951982008(In Chinese). van HarsselJJvan RoozendaalCEDetischYEfficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detectionFam Cancer91932012010 Caux-MoncoutierVCasteraLTirapoCEMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patientsHum Mutat323253342011 Kote-JaraiZLeongamornlertDSaundersEBRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsBr J Cancer105123012342011 SinclairCSAdemCNaderiATBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumorsCancer Res62358735912002 AdemCReynoldsCSoderbergCLPathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriersCancer971112003 van der HoutAHvan den OuwelandAMvan der LuijtRBA DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic settingHum Mutat276546662006 HermsenBBvan DiestPJBerkhofJLow prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancerInt J Cancer119141214182006 RomanoALindseyPJFischerDCTwo functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancerGynecol Oncol1012872952006 LevanatSMusaniVCvokMLThree novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in CroatiaGene4981691762012 HollomanWKUnraveling the mechanism of BRCA2 in homologous recombinationNat Struct Mol Biol187487542011 YangHJeffreyPDMillerJBRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structureScience297183718482002 SiaudNBarberaMAEgashiraAPlasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domainsPLoS Genet7e10024092011 FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol28251225192010 SpurdleABLakhaniSRHealeySClinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis - a report from the kConFab InvestigatorsJ Clin Oncol26165716632008 RischHAMcLaughlinJRColeDEPopulation BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, CanadaJ Natl Cancer Inst98169417062006 Figure and Tables

Novel mutations determined in Slovene probands. (a) Electropherogram of a single nucleotide substitution c.1193C>A in exon 11 of BRCA1, detected in proband no.275-11; this nonsense mutation resulted in a stop codon formation at amino acid position 398. (b) Electropherogram of a single nucleotide substitution c.5101C>T in exon 11 of BRCA2, detected in proband no.312-10; this nonsense mutation resulted in a stop codon formation at amino acid position 1701. (c) Electropherogram of a deletion of GGAA in exon 11 of BRCA2, detected in a proband no.658-11; the delition causing a frameshift mutation and formation of a stop codon at amino acid position 1814.

All pathogenic mutations in BRCA1 and BRCA2 detected in Slovene HBOC families.

Mutationa Amino acid changeb Type of mutation No. of positive families
BRCA1 c.66_67delAG p.Glu23Valfs*17 Frameshift 1
c.116G>A p.Cys39Tyr Missense 8
c.181T>G p.Cys61Gly Missense 31
c.181T>A p.Cys61Ser Missense 5
c.191G>A p.Cys64Tyr Missense 3
c.457_458delAG p.Ser153Cysfs*5 Frameshift 1
c.844_850dupTCATTAC p.Gln284Leufs*5 Frameshift 14
c.843_846delCTCA p.Ser282Tyrfs*15 Frameshift 2
c.1193C>A p.Ser398* Nonsense 1
c.1687C>T p.Gln563* Nonsense 23
c.2269_2270delG p.Val757Phefs*8 Frameshift 1
c.3018_3021delTTCA p.His1006Glnfs*17 Frameshift 3
c.3436_3439delTGTT p.Cys1146Leufs*8 Frameshift 1
c.3718C>T p.Gln1240* Nonsense 2
c.5177_5180delGAAA p.Arg1726Lysfs*3 Frameshift 2
c.5251C>T p.Arg1751* Nonsense 2
c.5266dupC p.Gln1756Profs*74 Frameshift 9
c.5377A>T p.Lys1793* Nonsense 3
Exon 1–2del Large deletion 2
Exon 5–10del Large deletion 4
Exon 5–8del Large deletion 1
Exon 5–7del Large deletion 3
BRCA2 c.262_263delCT p.Leu88Alafs*12 Frameshift 1
c.658_659delGT p.Val220Ilefs*4 Frameshift 1
c.775A>T p.Arg259* Nonsense 1
c.1528G>T p.Glu510* Nonsense 1
c.1773_1776delTTAT p.Ile591Metfs*22 Frameshift 1
c.1813insA p.Ile605Asnfs*11 Frameshift 1
c.3265C>T p.Gln1089* Nonsense 2
c.3975_3978dupTGCT p.Ser1328Cysfs*3 Frameshift 5
c.4936_4939delGAAA p.Glu1646Glnfs*23 Frameshift 1
c.5101C>T p.Gln1701* Nonsense 2
c.5213_5216delCTTA p.Thr1738Ilefs*2 Frameshift 1
c.5291C>G p.Ser1764* Nonsense 5
c.5351insA p.Asn1784Lysfs*3 Frameshift 1
c.5433_5436delGGAA p.Glu1811Aspfs*3 Frameshift 1
c.5609_5610delTCinsAG p.Phe1870* Nonsense 2
c.6491_6494delAGTT p.Gln2164Argfs*3 Frameshift 1
c.6641insC p.Thr2214Asnfs*10 Frameshift 1
c.6814delA p.Arg2272Glufs*8 Frameshift 1
c.7303C>T p.Gln2435* Nonsense 1
c.7806-2A>G aberrant splicing Splicing 13
c.8175G>A p.Trp2725* Nonsense 2
c.9117G>A p.Pro3039Pro Splicing 1
c.9286C>T p.Glu3096* Nonsense 1

Description of nucleotide variants is in accordance with HGVS nomenclature (DNA variants are numerated according to NCBI reference NM_007294.2 for BRCA1 and NM_000059.3 for BRCA2; the first nucleotide of the start codon ATG is numerated 1).

Description of amino acid change is in accordance with HGVS nomenclature.

Screening for mutations in BRCA genes in probands from HBOC families in Slovenia.

Period No. of tested probands No. of new families No. of new BRCA1 positive families No. of new BRCA2 positive families
January 1999 – December 2008a 521 322 68 28
January 2009 – December 2011 559 349 54 20
Total 1080 671 122 48

published in Stegel et al(10).

Novel pathogenic mutations in BRCA1 and BRCA2 genes.

Gene HGVS nomenclaturea BIC nomenclatureb Amino acid changec No. of families Proband characteristics (age at onset) Other confirmed carriers in the family Family history of the BC and/or OC (age at onset)
BRCA1 c.1193C>A 1312C>A p.Ser398* 1 Healthy, age 34 / Mother - BC (53)
Maternal aunt - BC (43) and OC (54)
BRCA2 c.5101C>T 5329C>T p.Gln1701* 2 BC (39) Healthy daughter, age 34 /
OC (49) and BC (51) Healthy daughter, age 31 Mother - OC (73)
Healthy sister, age 51
Healthy sister’s daughter, age 30
c.5433_5436delGGAA 5661_5664delGGAA p.Glu1811Aspfs*3 1 BC (53) / Maternal grandmother - BC (54)
Maternal aunt - BC (57)
Maternal cousin - bilateral BC (38, 62)

Description of nucleotide variants is in accordance with HGVS nomenclature (DNA variants are numerated according to NCBI reference NM_007294.2 for BRCA1 and NM_000059.3 for BRCA2; the first nucleotide of the start codon ATG is numerated 1) or

BIC nomenclature (DNA variants are numerated according to NCBI reference HSU14680 for mRNA of BRCA1 and U43746 for mRNA of BRCA2).

Description of amino acid change is in accordance with HGVS nomenclature. BC, breast cancer; OC, ovarian cancer.

Known BRCA1 pathogenic mutations that have been detected for the first time in Slovene HBOC families

HGVS nomenclaturea BIC nomenclatureb Amino acid changec No. of families Proband characteristics (age at onset) Other confirmed carriers in the family Family history of BC and OC (age at onset) Other cancers in the family (age at onset)
c.66_68delAG 185_186delAG p.Glu23Valfs*17 1 BC (39), OC (42) / Mother - BC (45) Maternal aunt - UC (73)
c.3436_3439delTGTT 3555_3558delTGTT p.Cys1146Leufs*8 1 OC (55) Healthy daughter, age 31 Sister - OC (53) /
Sister - BC (66)
Mother - BC (75)
c.3718C>T 3837C>T p.Gln1240* 2 BC (60) / Sister - bilateral BC (46, 49) Maternal uncle - LC (57)
Mother - OC (69) Maternal aunt - FTC (56)
Maternal aunt - OC (65)
Maternal aunt - BC (70)
OC (38) Paternal aunt - OC (41) Father - PC (74)
Paternal aunt - BC (42) and OC (56) Sister - CC (32)
Paternal aunt - CRC (51)
Paternal aunt - OC (71)

Description of nucleotide variants is in accordance with HGVS nomenclature (DNA variants are numerated according to NCBI reference NM_007294.2 for BRCA1; the first nucleotide of the start codon ATG is numerated 1) or

BIC nomenclature (DNA variants are numerated according to NCBI reference HSU14680 for mRNA of BRCA1).

Description of amino acid change is in accordance with HGVS nomenclature. BC, breast cancer; OC, ovarian cancer; UC, uterine cancer; LC, liver cancer; FTC, fallopian tube cancer; PC, prostate cancer; CC, cervical cancer; CRC, colorectal cancer.

Known BRCA2 pathogenic mutations that have been detected for the first time in Slovene HBOC families

HGVS nomenclaturea BIC nomenclatureb Amino acid changec No. of families Proband characteristics (age at onset) Other confirmed carriers in the family (age at onset) Family history of BC and OC (age at onset) Other cancers in the family (age at onset)
c.262_263delCT 490_491delCT p.Leu88Alafs*12 1 BC (46) / Sister - BC (55) Mother - EC (44)
Father - BRC (56)
c.658_659delGT 886_887delGT p. Val220Ilefs*4 1 BC (72) and OC (74) / Sister - OC (59) /
Sister - OC (64)
Sister - OC (78)
c.1773_1776delTTAT 2001_2004delTTAT p.Ile591Metfs*22 1 BC (54) Daughter - BC (38) Healthy daughter, age 37 Mother - BC (68) /
c.5213_5216delCTTA 5441_5444delCTTA p.Thr1738Ilefs*2 1 OC (54) Healthy daughter, age 35 Mother - BC (35) /
c.6641insC 6869insC p.Thr2214Asnfs*10 1 BC (47) / Sister - BC (36) /
Brother - BC (44)
c.6814delA 7042delA p.Arg2272Glufs*8 1 BC (32) / Mother - bilateral BC (58) Maternal grandmother - GC (70)
Maternal aunt - BC (59) Maternal aunt - BRC (63)
c.8175G>A 8403G>A p.Trp2725* 2 BC (43) Healthy brother, age 43 Mother - BC (46) /
Paternal grandmother - BC (72)
Paternal aunt - BC (31)
Paternal aunt - BC (41)
BC (26) / Mother - BC (45) /
Maternal grandmother - BC (65)
c.9117G>A 9345G>A p.Pro3039Pro 1 BC (49) Daughter - OC (24) Healthy daughter, age 24 Daughter - OC (24) Mother - CHC (53)

Description of nucleotide variants is in accordance with HGVS nomenclature (DNA variants are numerated according to NCBI reference NM_000059.3 for BRCA2; the first nucleotide of the start codon ATG is numerated 1) or

BIC nomenclature (DNA variants are numerated according to NCBI reference U43746 for mRNA of BRCA2).

Description of amino acid change is in accordance with HGVS nomenclature. BC, breast cancer; OC, ovarian cancer; EC, endometrial carcinoma; BRC, brain cancer; GC, gastric cancer; CHC, cholangiocarcinoma.